Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Simple, Inexpensive Genetic Test Can Identify MS Patients at Risk of Fatal Brain Infection

By LabMedica International staff writers
Posted on 20 Mar 2023

Patients with multiple sclerosis (MS) are confronted with a difficult decision - whether they should take medications that have proven to be effective in slowing the disease's progression, despite the potential risk of triggering a fatal brain infection called progressive multifocal leukoencephalopathy (PML). More...

This rare complication occurs when the JC virus, which is prevalent but usually dormant in most carriers, becomes active. Immune-modifying medications, including those prescribed for MS treatment, have been linked to PML in rare cases. As more potent immunosuppressive drugs become available, drug-induced PML is becoming increasingly common.

Now, leading MS experts are recommending genetic testing to identify MS patients with an increased likelihood of experiencing serious medication side effects. Joseph Berger, MD, MS Division Chief at the University of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), and Hans-Peter Hartung, MD, Neurology Chair of Heinrich Heine University (Düsseldorf, Germany), have come out in support of a new study that confirms a strong link between four genetic mutations and PML. These mutations were found to be significantly more common in MS patients who took PML-linked drugs and later developed PML compared to those who took similar medications but did not develop PML.

"The availability of a simple, relatively inexpensive test that can identify the genes that put one at risk for PML would be enormously helpful in the management of patients. The widespread use of such testing could potentially allow the physician to use alternative therapies that do not carry the same risk of PML," stated Drs. Berger and Hartung.

Related Links:
University of Pennsylvania Perelman School of Medicine
Heinrich Heine University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Platelet Function Analyzer
PL-12
Gold Member
Platelet Function Analyzer
AGGRENG-40
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.